Company intelligence / Profile preview

Arranta Bio

Watertown, Massachusetts, United Statesrecipharm.com ↗

Ownership: Private
Employees: ~170
Development stage: Commercial

Overview

Arranta Bio does not have its own clinical pipeline but provides advanced development and GMP/commercial-scale manufacturing services for client programs in the microbiome and mRNA therapeutic spaces. It has expanded into rapid continuous mRNA vaccine/therapeutic production through academic partnerships.

Modalities: Live biotherapeutic product therapymRNA-based drugsBiologicPlasmid DNA manufacturing
Industry: Contract Manufacturing Organization

Partnerships

Massachusetts Institute of Technology (MIT)Rensselaer Polytechnic InstitutePennsylvania State University

Beyond the preview

Go deeper on Arranta Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arranta Bio.

Explore the full profile